Robert F. Kennedy had dinner with Pfizer CEO as he prepares to become health secretary, report says - Pfizer CEO certain that ...

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

Healthcare was the only sector in the red by afternoon trading on the ASX, following a similar retreat on Wall Street ...

Other fact-checking organizations have debunked the claim; Reuters and AFP have also fact-checked similar claims that circulated in 2022 and 2023 ...

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management ...

Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health sector.

CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...

Shares of companies developing psychedelic treatments jumped while those of vaccine makers slipped after a Senate committee advanced the nomination of Robert F. Kennedy Jr. to lead the Health and ...

Pfizer Inc. (NYSE: PFE) shares are trading lower Tuesday after the Senate Finance Committee voted to advance Robert F. Kennedy Jr.'s nomination for Secretary of Health and Human Services.

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...

Pfizer also reaffirmed its full-year 2025 guidance, which includes revenue in a range of $61 billion to $64 billion and adjusted earnings between $2.80 and $3 a share. Analysts surveyed by FactSet are ...